CLDN2 and breast carcinoma: To investigate potential binding partners that interact via the PDZ-binding motif of Claudin-2, we generated hemagglutinin (HA)-tagged versions of both wild-type and the Claudin-2 ΔPDZ BD mutant and expressed them in liver-aggressive 4T1 breast cancer cells (2776) (Supplemental Fig. S3A).